The EPS beat and pipeline catalysts (PYLARIFY TruVu, PNT2003) could drive short-term bullish momentum, but declining adjusted EPS and PYLARIFY erosion warrant caution. Watch for updates on PYLARIFY TruVu conversion and PNT2003 full approval.
Price Chart
Executive Summary
Lantheus reported Q1 2026 revenue of $377.3M (beat consensus $354.4M) and adjusted EPS of $1.46 (beat $1.23), but adjusted EPS declined 4.6% YoY. GAAP EPS surged to $1.80 on a $59.3M gain from the SPECT divestiture. FY2026 guidance was reaffirmed. Results are mixed: strong beat vs consensus but declining core profitability and PYLARIFY sales down 6.5%.
Key Financial Metrics
Key Facts
- Q1 2026 revenue $377.3M, +1.2% YoY
- GAAP diluted EPS $1.80 vs $1.02 YoY
- Adjusted diluted EPS $1.46 vs $1.53 YoY (-4.6%)
- Consensus was $1.23 EPS and $354.4M revenue
- PYLARIFY sales $240.9M, -6.5% YoY
- Neuraceq sales $35.4M, new product growth
- FY2026 guidance reaffirmed: revenue $1.4B-$1.45B, adj. EPS $5.00-$5.25
- Free cash flow $121.9M vs $98.8M YoY
- FDA approved PYLARIFY TruVu; tentative approval for PNT2003
Financial Impact
Revenue beat by $22.9M (6.5%), adjusted EPS beat by $0.23 (18.7%)
Risk Factors
- PYLARIFY sales continue to decline due to competition
- Adjusted profitability declining YoY
- Integration costs from acquisitions may pressure margins
- Delays or setbacks in FDA approvals or launch timelines
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-210369 |
| Document: lnth-20260507.htm | 0001193125-26-210369 |
| Document: 0001193125-26-210369-index-headers.html | 0001193125-26-210369 |
| Document: 0001193125-26-210369-index.html | 0001193125-26-210369 |
| Document: 0001193125-26-210369.txt | 0001193125-26-210369 |
| 8-K Data (Synthetic) | 0001193125-26-210369 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 8-K | $100.10 $99.80 | ▼ −0.30% | ▲ +0.22% | $100.15 (+0.05%) |
Oct 2, 2026 25d ago | DEFA14A | $100.19 $99.95 | ▼ −0.24% | ▼ −0.79% | $100.15 (−0.04%) |
Oct 2, 2026 25d ago | 8-K | $100.19 $99.95 | ▼ −0.24% | ▼ −0.79% | $100.15 (−0.04%) |
Sep 16, 2026 5w ago | DEFA14A | $100.80 $100.55 | ▼ −0.25% | ▼ −0.38% | $100.15 (−0.64%) |
Aug 26, 2026 8w ago | PREM14A | $100.82 $100.47 | ▼ −0.35% | ▼ −1.00% | $100.15 (−0.66%) |
Aug 14, 2026 10w ago | Press Release | $100.95 $100.91 | ▼ −0.04% | ▲ +0.43% | $100.15 (−0.79%) |
Aug 6, 2026 11w ago | 8-K | $101.07 $100.95 | ▼ −0.12% | ▼ −0.73% | $100.15 (−0.91%) |
Aug 3, 2026 12w ago | 8-K / DEFA14A | $101.11 $101.50 | ▲ +0.39% | ▲ +0.59% | $100.15 (−0.95%) |
Aug 3, 2026 12w ago | DEFA14A / 8-K | $101.19 $101.11 | ▼ −0.08% | ▼ −1.88% | $100.15 (−1.03%) |
Aug 3, 2026 12w ago | Press Release | $101.19 $101.11 | ▼ −0.08% | ▼ −1.88% | $100.15 (−1.03%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers